Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.16 -0.11 (-2.58%)
price chart
Arena Pharmaceuticals, Inc. (ARNA) Jumps: Stock Rises 9.5%
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.
Related articles »  
5 Things Arena Pharmaceuticals, Inc.'s Management Wants You to Know
Arena Pharmaceuticals (NASDAQ: ARNA ) held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline.
Belviq And Phentermine Study Awes Some Investors - Should It? (ARNA)  Seeking Alpha (registration)
Related articles »  
Why Arena Pharmaceuticals, Inc. Stock Crashed By 31% in 2014
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals (NASDAQ: ARNA ) have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech ...
Arena Pharmaceuticals - A Biotech Value Investment  Seeking Alpha (registration)
Investor's Watch List ´┐ŻArena Pharmaceuticals, Inc. (NASDAQ:ARNA), Image ...  Techsonian (press release)
Related articles »  
Belviq Sales Recover From Holiday Dip
Arena Pharmaceuticals' (NASDAQ:ARNA) anti-obesity pill Belviq saw a full recovery from a holiday dip in sales last week with a 15% gain this week.
Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Related articles »  
Surprising New Competitor: Should Arena Pharmaceuticals, Inc. and Orexigen ...
Editor's Note: The article below was updated to clarify that Saxenda is a 3 mg dose of liraglutide, as compared to Victoza (1.2/1.8 mg dose).
Novo, Orexigen Join Race For Obesity Drugs; Arena-Eisai's Belviq And ...  Bidness ETC
New anti-obesity drug is OK'd  Nashua Telegraph
Related articles »  
Arena Down On The Back Of Weigh-Loss Drug Failure
The biotech sector has performed well this year, with Intercept Pharmaceuticals Inc. (ICPT) and Gilead Sciences, Inc. (GILD) topping the list. Most biopharmaceuticals have so far registered positive gains in 2014, after overcoming the momentum sell-off ...
FDA panel backs Novo Nordisk drug for obesity  Daily Item
FDA panel backs Novo Nordisk injection  NEWS.com.au
Related articles »  
Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary ...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, -2.58% today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.
Arena Pharmaceuticals' APD811 Gets Orphan Drug Status - Analyst Blog  NASDAQ
Related articles »  
Did VIVUS and Arena Pharmaceuticals Just Turn the Corner? (ARNA, VVUS)
Well, it was nowhere close to the way investors of VIVUS, Inc. (NASDAQ:VVUS) and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) would have envisioned it happening two years ago, in terms of time or reason.
Why Turned Attractive? - VIVUS, Inc. (NASDAQ:VVUS), EMCORE Corporation ...  Markets Emerging
Biotech Active Stocks: VIVUS Inc. (NASDAQ:VVUS), Gilead Sciences Inc ...  WallStreet Scope
Related articles »  
Don't Miss : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Caterpillar Inc ...
Contrave is a combination of two Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Vivus Inc. drugs that were approved by the FDA in 2012, ABC News reports, after having spent 13 years without approving any weight-loss medication.